Skip to main content

Table 4 Studies on LPD for pancreatic cancer

From: Expanding laparoscopic pancreaticoduodenectomy to pancreatic-head and periampullary malignancy: major findings based on systematic review and meta-analysis

 

Croome

Hakeem

Chen

Song

Dokmak

Stauffer

Kantor

Conrad

Palanivelu

Khaled

Meng

Age (years)

66.6 ± 9.6

67.0 ± 10.2

–

68.1 ± 7

–

69.9(40.6–84.8)

65.9 ± 10.7

68(45–83)

57.8 ± 2.0

65(35–78)

60.0 ± 9.1

Sex (M/F)

57/51

8/4

–

–

–

32/26

–

26/14

18/14

8/7

32/26

BMI

27.4 ± 5.4

25.8 ± 3.7

–

–

–

25.9(17.7–49.6)

–

23.9(14.9–34.1)

24.9 ± 0.7

23.4(18–26)

22.3 ± 3.0

Tumor size (cm)

3.3 ± 1.0

2.0 ± 1.0

3.0 ± 0.9

2.8 ± 0.6

2.4(1.5–4)

2.5(0.3–10.0)

–

2.5 (0.3–8.0)

3.3 ± 0.7

2.0(0.7–8.0)

1.9(1.5–2.6)

Retrieved LNs

21.4 ± 8.1

20.7 ± 6.3

18.1 ± 6.6

15 ± 10

20(8–59)

27(9–70)

18.1 ± 9.5

18(6–53)

18.9 ± 1.0

18(14–19)

16(15–18)

R0 rate

77.8%

75.0%

94.7%

72.7%

60%

84.5%

79.1%

87.5%

96.9%

86.7%

100%

Operative time (min)

379.4 ± 93.5

–

–

–

–

518(313–761)

–

–

359 ± 14

470(280–660)

475(420–546)

Blood loss (mL)

492.4 ± 519.3

–

–

–

–

250(50–8500)

–

–

250 ± 22

300(50–600)

200(100–325)

POPF

–

16.7%

–

–

20%

11.8%

–

30%

15.6%

20.0%

55.2%

Significant POPF

11%

–

–

–

–

7.8%

–

–

6.3%

20.0%

13.8%

Morbidity

5.6% CD>2

58.3%

–

–

53%

53.4%

–

95%

25.0%

40.0%

15.5% CD>2

Hospital stay (days)

6 (4–118)

14.9 ± 6.6

–

–

15(6–53)

6(4–68)

10.2 ± 8.5

24.5(9–311)

7(5–52)

9.0(7–20)

14.0(11.0–17.3)

Readmission

–

–

–

–

–

22.4% 90d

6.8% 30d

–

6.3% 90d

–

–

Mortality

0.9% 30d

0% 30d

–

0% 30d

0% 90d

3.4% 90d

6.9% 90d

5% 90d

3.1% 90d

0% 30d

1.7% 30d

Survival

MS: 25.3 m

1,3,5y-DFS:100,92,83%; 1,3,5y-OS:100,92,75%.

–

5y-OS:

53.6%

–

1,2,3,4,5y-OS:

66.5,43.3,43.3%,

38.5,32.1%

MS: 20.7 m

MS: 35.5 m;

1,3,5y-DFS: 62.3, 37.9, 25.7%; 1,3,5y-OS: 80.5, 49.2, 39.7%

–

1,3,5y-OS: 100, 80, 67%

MS: 45 m

  1. OS overall survival rate, MS median survival time, m month